Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study

Clinical trial NCT07696832 · RECRUITING

Trial details

NCT number: NCT07696832
Sponsor: Guangdong Association of Clinical Trials
Status: RECRUITING
Study type: OBSERVATIONAL

Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC EGFR Mutation-negative and ALK Rearrangement-negative Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 0 to 2 No Prior Systemic Therapy Received for the Advanced or Metastatic Disease PD-L1 Positive, as Determined by a Validated Assay

Start date: 2026-01-20
Primary completion: 2027-05-15
Enrollment: 265

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.